A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

By Michael Gibney • July 25, 2022

Behind Pfizer's new quest to target a 'transformation' in pharma

A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

By Kelly Bilodeau • July 25, 2022

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Moderna's next vax target? A little-known cause of birth defects

How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.

By Karissa Waddick • July 21, 2022

By the numbers: The rising danger of superbugs

A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.

By Karissa Waddick • July 20, 2022

Woman of the Week: Vaxxinity's Mei Mei Hu

Mei Mei Hu is looking to lead a third biologic ‘revolution’ by developing vaccines for chronic diseases.

By Taren Grom • July 20, 2022

Biotech R&D spending has skyrocketed, and so have opportunities for savings

With R&D costs on the rise, biotechs are embracing new strategies and technologies to make spending more efficient.

By Michael Gibney • July 19, 2022

Making moves: Agios, BeiGene, Biocom California and more announce new key hires

The latest executive personnel changes from around the industry.

By Karissa Waddick • July 18, 2022

Anjarium Biosciences’ CEO on its next-gen gene therapies

Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.

By Kim Ribbink • July 15, 2022

Alkermes looks to fill cancer treatment gaps with new immune pathways

The company’s chief medical officer discusses its lead candidate and how it fits into wider oncology trends.

By Kelly Bilodeau • July 14, 2022

Woman of the Week: Kura Oncology's Kirsten Flowers

How the chief commercial and corporate strategy officer is embracing a ‘full-cup’ philosophy to build a better leadership toolbox.

By Taren Grom • July 13, 2022

Why a 'fundamental shift' in regulatory submissions is on the way

Deloitte's senior manager of R&D and regulatory practices explains how technology and strategy must converge to smooth out the bulky drug approval process.

By Michael Gibney • July 11, 2022

Precision closes in on what could become the first 'off-the-shelf' CAR-T cell therapy

Precision BioSciences’ CEO discusses the company’s potentially groundbreaking cancer treatment.

By Kelly Bilodeau • July 7, 2022

The CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing

Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.

By Meagan Parrish • July 7, 2022

How Big Pharma is prepping for the late 2020s patent cliff

Ratings agency Moody’s lays out the risk exposure for industry leaders.

By Kim Ribbink • July 6, 2022

Woman of the Week: CinCor Pharma's Terry Coelho

From M&Ms to biotech, the chief financial officer's sweet tooth for taking risks is paying off. 

By Taren Grom • July 6, 2022

Pharma companies take a fresh approach to inclusion in new DTC ads

AstraZeneca and Amgen are emphasizing diversity and authenticity in campaigns for lupus and severe asthma therapies.

By Karissa Waddick • July 5, 2022

Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

By Kim Ribbink • June 30, 2022

The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman

The two Penn Medicine researchers whose work brought the mRNA vaccines into COVID-19 fruition want to see the pharma world embrace early science.

By Michael Gibney • June 29, 2022

Making moves: Walgreens, Merck, eClinical Solutions and more announce key new hires

The latest personnel changes from around the industry.

By Karissa Waddick • June 29, 2022

A myriad of blows: Who's getting hit the hardest by the economy's troubles

The downturn shows few signs of hurting large pharma, but small biotechs and generics makers could face a credit crunch.

By Kim Ribbink • June 27, 2022

From vineyards to antivirals, Gilly Regev brings creative thinking to science

The CEO of SaNOtize is tapping into outside-the-box innovation to develop a nitric oxide-delivery platform to treat and prevent COVID-19.

By Alexandra Pecci • June 27, 2022

4 tips for landing your next C-suite role in pharma

Even execs get the blues — and when they’re ready for a fresh start, Leslie Loveless, CEO of Slone Partners, says these dos and don’ts could make or break their next job move.

By Meagan Parrish • June 23, 2022

Woman of the Week: Kronos Bio's Barbara Kosacz

Deal-maker, mentor and biotech industry mover and shaker, the COO and general counsel brings her 'smiling tiger' skills to her new role at the emerging company.

By Taren Grom • June 21, 2022

#DIA2022: How the industry's top regulator views the future of healthcare

In the evolution of healthcare, data is the linchpin to making drug development more efficient.

By Michael Gibney • June 21, 2022

Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience

An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

By Kim Ribbink • June 16, 2022